Get Started

BCAX

NASD Bicara Therapeutics Inc.
Nov 6, 2026 · 5:56 PM ET LAST TRADE Market Closed

$8.65 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.65, $0.28 below the day’s high of $8.93

YTD change
-48.60%
vs 20-day SMA
-40.20%
vs 200-day SMA
-58.89%

Price ranges

Previous day
$8.15 $8.90
open $8.82 close $8.19
-$0.63 (-7.14%)
Today
$8.06 $8.93
open $8.32 now $8.65
+$0.33 (+3.97%)
Past week
$7.87 $9.73
from $9.73 now $8.65
-$1.08 (-11.10%)
Past month
$7.87 $18.78
from $17.26 now $8.65
-$8.61 (-49.88%)
This year
$7.87 $30.99
from $16.83 now $8.65
-$8.18 (-48.60%)

Price & Performance

-15.59 (-65.56%) / 6M

$6.13$14.82$23.51$32.20May 6Aug 6Nov 5

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 72.1% away from all-time highs of $30.99
  • BCAX is down 49% since the beginning of the year
  • BCAX is down 41% over the past 12 months
  • BCAX is down 50% over the past 1 month
  • 18% of all BCAX investors are betting against BCAX

BCAX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -43.8%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.82
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $60.2M
Beta -0.34

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$497.3M
Debt$1.2K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $572.4M

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,364.73 -3.76%
JNJ Johnson & Johnson $272.32 -1.45%
ABBV AbbVie, Inc. $288.24 -2.24%
MRK Merck & Co., Inc. $146.94 -2.27%
RHHBY Roche Holding Ltd Sponsored ADR $59.45 -2.45%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.